ALK and non-small cell lung carcinoma: Compared to ceritinib or ensartinib, APG-2449 exhibits greater antitumor activity against crizotinib-resistant tumors lacking secondary ALK mutations, indicating that APG-2449 may be effective in a large proportion of patients with ALK inhibitor-resistant NSCLC irrespective of ALK genotype.